January 9th 2025
These new regulatory developments put CUTX-101 on track to become the first FDA-approved treatment for patients with Menkes disease.
FDA Receives 2 Supplemental Biologics License Applications for Guselkumab for Pediatric Indications
December 3rd 2024If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.
Read More
Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease
November 29th 2024Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.
Read More